{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T14:49:01Z","timestamp":1758293341272,"version":"3.44.0"},"reference-count":12,"publisher":"Endocrinology Research Centre","issue":"4","license":[{"start":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T00:00:00Z","timestamp":1757808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>A woman spends more than a third of her life in a state of deficiency of female sex hormones. According to WHO, in most countries of the world the life expectancy of women after 50 years fluctuates between 27 and 32 years. Every year the number of women entering the menopause period increases. In 1990, 467 million were in the postmenopause period, by 2030 the number will reach 1.2 billion. Menopause, not being a disease itself, leads to a violation of the endocrine balance in the body, causing not only \u00abclassic\u00bb problems in life (vasomotor symptoms, psychological health disorders, urogenital disorders, osteoporosis, cardiovascular diseases), but also changes the appearance of women \u2014 the dermatological status of the patient is worse than the age group. The article presents modern data on rational MHT. Particular attention is paid to the issues of efficacy, tolerability and safety of combined MHT containing estrogen and gestagen, based on the results of current studies and in accordance with the position of national and international clinical guidelines. A clinical case is used to demonstrate the tactics of managing a woman in menopause.<\/jats:p>","DOI":"10.14341\/probl13644","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T13:23:44Z","timestamp":1758201824000},"page":"95-102","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":0,"title":["Healthy longevity of women: what can a gynecologist do?"],"prefix":"10.14341","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8425-0020","authenticated-orcid":true,"given":"E. N.","family":"Andreeva","sequence":"first","affiliation":[{"name":"I.I. Dedov Endocrinology Research Centre;\r\nRussian University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7177-0254","authenticated-orcid":true,"given":"E. V.","family":"Sheremetyeva","sequence":"additional","affiliation":[{"name":"I.I. Dedov Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4979-7420","authenticated-orcid":true,"given":"O. R.","family":"Grigoryan","sequence":"additional","affiliation":[{"name":"I.I. Dedov Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2025,9,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"\u0410Andreeva EN, Sheremetyeva EV, Grigoryan OR, Altaeva AA. The effect of menopausal hormone therapy on the dermatological status of postmenopausal women or an interdisciplinary approach in anti-age protocols for the integrated management of postmenopausal women. Russian Journal of Human Reproduction. 2023;29(2):70-80. (In Russ.). doi: https:\/\/doi.org\/10.17116\/repro20232902170","DOI":"10.17116\/repro20232902170"},{"key":"ref2","unstructured":"World report on ageing and health. WHO Library Cataloguing-in-Publication Data 2016"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Tapilskaya N.I., Bespalova O.N., Kogan I.Yu. Justification for the choice of menopausal hormone therapy when there is a need to change treatment in the context of a personalized approach. \/\/ Obstetrics and Gynecology. \u2014 2022; \u2014 No. 10. \u2014 P. 178-184. doi: https:\/\/dx.doi.org\/10.18565\/aig.2022.10.178-184","DOI":"10.18565\/aig.2022.10.178-184"},{"key":"ref4","unstructured":"Ulumbekova G.E., Khudova I.Yu. Assessment of the demographic, social and economic effect of menopausal hormone therapy. ORGZDRAV: news, opinions, training. \/\/ Bulletin of the Higher School of Health. \u2014 2020. \u2014 Vol. 6. \u2014 No. 4. \u2014 P. 23-53. doi: https:\/\/dx.doi.org\/10.24411\/2411-8621-2020-14002."},{"key":"ref5","unstructured":"Clinical guidelines (project) \u00abMenopause and climacteric condition\u00bb, Moscow, 2024"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Algorithms for the use of menopausal hormone therapy in women during the peri- and postmenopause. Joint position of experts of the Russian Society of Obstetricians and Gynecologists, Russian Academy of Medical Sciences, the Academy of Gynecology and Public Health, and the Russian Academy of Organ and Organ Society \/ edited by V.N. Serov, S.V. Yureneva. \/\/ Obstetrics and Gynecology. \u2014 2021. \u2014 No. 3. \u2014 P. 210-221. doi: https:\/\/dx.doi.org\/10.18565\/aig.2021.3.210-221","DOI":"10.18565\/aig.2021.3.210-221"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Yureneva S.V., Dubrovina A.V. Advantages of early\/timely start of menopausal hormone therapy from the standpoint of the theory of euestrogens. \/\/ Russian Bulletin of Obstetrician-Gynecologist. \u2014 2018. \u2014 Vol. 18. \u2014 No. 5. \u2014 P. 49-55.","DOI":"10.17116\/rosakush20181805149"},{"key":"ref8","unstructured":"NICE guideline Menopause: diagnosis and management (NG23, published Nov 2015). Available at: nice.org.uk\/guidance\/NG23. Accessed 20 Jan 2021"},{"key":"ref9","unstructured":"Rules for conducting bioequivalence studies of medicinal products within the framework of the Eurasian Economic Union (Decision of the Council of the Eurasian Economic Commission of November 3, 2016 No. 85)"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"\u201cThe 2023 Nonhormone Therapy Position Statement of The North American Menopause Society\u201d Advisory Panel. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. doi: https:\/\/doi.org\/10.1097\/GME.0000000000002200","DOI":"10.1097\/GME.0000000000002200"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Cameron CR, Cohen S, Sewell K, Lee M. The Art of Hormone Replacement Therapy (HRT) in Menopause Management. J Pharm Pract. 2024;37(3):736-740. doi: https:\/\/doi.org\/10.1177\/08971900231167925","DOI":"10.1177\/08971900231167925"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Yang JL, Hodara E, Sriprasert I, Shoupe D, Stanczyk FZ. Estrogen deficiency in the menopause and the role of hormone therapy: integrating the findings of basic science research with clinical trials. Menopause. 2024;31(10):926-939. doi: https:\/\/doi.org\/10.1097\/GME.0000000000002407","DOI":"10.1097\/GME.0000000000002407"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13644\/10895","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T13:24:12Z","timestamp":1758201852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,14]]},"references-count":12,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,9,14]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13644","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"type":"electronic","value":"2308-1430"},{"type":"print","value":"0375-9660"}],"subject":[],"published":{"date-parts":[[2025,9,14]]}}}